BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 16802535)

  • 1. [Therapy of acute decompensated heart failure with levosimendan].
    Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
    Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
    Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G
    Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.
    Russ MA; Prondzinsky R; Christoph A; Schlitt A; Buerke U; Söffker G; Lemm H; Swyter M; Wegener N; Winkler M; Carter JM; Reith S; Werdan K; Buerke M
    Crit Care Med; 2007 Dec; 35(12):2732-9. PubMed ID: 17893627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
    Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
    J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI
    Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
    Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance.
    Tsagalou EP; Kanakakis J; Anastasiou-Nana MI; Drakos SG; Ntalianis AS; Malliaras K; Lazaris N; Katsaros F; Nanas JN
    Acute Card Care; 2009; 11(2):99-106. PubMed ID: 19353405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
    Wang L; Cui L; Wei JP; Li GP; Qi GX; Hao YM; Wang WZ; Li HM; Liu J; Jiang DJ; Zhang YD
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ST-segment elevation during levosimendan infusion.
    Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
    Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
    Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
    Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
    Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery.
    Labriola C; Siro-Brigiani M; Carrata F; Santangelo E; Amantea B
    Int J Clin Pharmacol Ther; 2004 Apr; 42(4):204-11. PubMed ID: 15124978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.